BTBD9 Antibody / BTB/POZ domain-containing protein 9
| Code | Size | Price |
|---|
| NSJ-V5123-20UG | 20 ug | £264.00 |
Quantity:
| NSJ-V5123-100UG | 100 ug | £534.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Mouse
Antibody Isotype: Mouse IgG1, kappa
Antibody Clonality: Monoclonal
Antibody Clone: BTBD9/7501
Regulatory Status: RUO
Target Species: Human
Application: Immunohistochemistry- Paraffin Embedded (IHC-P)
Storage:
Aliquot the BTBD9 antibody and store frozen at -20°C or colder. Avoid repeated freeze-thaw cycles.
Documents
Further Information
Application Details:
Immunohistochemistry (FFPE): 1-2ug/ml for 30 min at RT
Description:
BTBD9 (BTB/POZ domain-containing protein 9) is a 612 amino acid protein that contains one BTB/POZ domain and one BACK (BTB/Kelch associated) domain. The BTB/POZ domain mediates homomeric and heteromeric POZPOZ interactions and is common to transcriptional regulators involved in chromatin modeling. In several BTB/POZ containing proteins, including Bcl-6 and the promyelocytic leukemia zinc-finger (PLZF) oncoprotein, this domain interacts with the SMRT/N-CoR-mSin3A HDAC complex and is directly involved in repressing and silencing gene transcription. When this domain is deleted, as with the oncogenic PLZF-RAR chimera of promyelocytic leukemias, this transcriptional repression is attenuated. This suggests that BTBD9 may play a role in transcription regulation. Genetic variations in the gene that encodes BTBD9 have been associated with susceptibility to restless legs syndrome type 6 (RLS6), a condition characterized by an uncontrollable urge to move the legs while resting.
Format:
Purified
Formulation:
0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced), 0.05% sodium azide
Immunogen:
A recombinant partial protein sequence (within amino acids 200-400) from the human protein was used as the immunogen for the BTBD9 antibody.
Limitation:
This BTBD9 antibody is available for research use only.
Localization:
Nucleus, Cytoplasm
Purity:
Protein A/G affinity
Uniprot #:
Q96Q07